Goar Smbatyan
Overview
Explore the profile of Goar Smbatyan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng Q, Dai Z, Smbatyan G, Epstein A, Lenz H, Zhang Y
Mol Ther
. 2022 Jun;
30(9):3066-3077.
PMID: 35746867
Exosomes are cell-derived nanovesicles involved in regulating intercellular communications. In contrast to conventional nanomedicines, exosomes are characterized by unique advantages for therapeutic development. Despite their major successes in drug delivery,...
2.
Ghate N, Kim S, Spiller E, Kim S, Shin Y, Rhie S, et al.
Mol Oncol
. 2021 Jul;
15(10):2801-2817.
PMID: 34312968
Histone modification is aberrantly regulated in cancer and generates an unbalanced state of gene transcription. VprBP, a recently identified kinase, phosphorylates histone H2A on threonine 120 (T120) and is involved...
3.
Dai Z, Zhang X, Cheng Q, Fei F, Hou T, Li J, et al.
J Control Release
. 2021 Jul;
336:433-442.
PMID: 34197861
Random conjugations of chemotherapeutics to monoclonal antibodies result in heterogeneous antibody-drug conjugates (ADCs) with suboptimal pharmacological properties. We recently developed a new technology for facile generation of homogeneous ADCs by...
4.
Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V, et al.
Sci Adv
. 2020 Nov;
6(46).
PMID: 33188023
Elucidating signaling driven by lemur tyrosine kinase 3 (LMTK3) could help drug development. Here, we solve the crystal structure of LMTK3 kinase domain to 2.1Å resolution, determine its consensus motif...
5.
Dai Z, Zhang X, Nasertorabi F, Cheng Q, Li J, Katz B, et al.
Sci Adv
. 2020 Jun;
6(23):eaba6752.
PMID: 32537509
Most of the current antibody-drug conjugates (ADCs) in clinic are heterogeneous mixtures. To produce homogeneous ADCs, established procedures often require multiple steps or long reaction times. The introduced mutations or...
6.
Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang J, et al.
Mol Ther
. 2019 Dec;
28(2):536-547.
PMID: 31843452
Exosomes are nanosized membranous vesicles secreted by a variety of cells. Due to their unique and pharmacologically important properties, cell-derived exosome nanoparticles have drawn significant interest for drug development. By...
7.
Ring A, Nguyen C, Smbatyan G, Tripathy D, Yu M, Press M, et al.
Cancers (Basel)
. 2018 Dec;
10(12).
PMID: 30572639
Triple negative breast cancers (TNBCs) are an aggressive BC subtype, characterized by high rates of drug resistance and a high proportion of cancer stem cells (CSC). CSCs are thought to...
8.
Cheng Q, Shi X, Han M, Smbatyan G, Lenz H, Zhang Y
J Am Chem Soc
. 2018 Nov;
140(48):16413-16417.
PMID: 30452238
Exosomes are naturally occurring membranous vesicles secreted by various types of cells. Given their unique and important biological and pharmacological properties, exosomes have been emerging as a promising form of...
9.
Zhao Y, Wu K, Wu Y, Melendez E, Smbatyan G, Massiello D, et al.
Curr Mol Pharmacol
. 2017 Sep;
11(2):113-121.
PMID: 28933312
Background And Objective: The development of the tyrosine kinase inhibitor Imatinib (IM) represents a milestone in CML (Chronic Myeloid Leukemia) treatment. However, it is not curative and patients develop IM...
10.
Zhao Y, Wu K, Nguyen C, Smbatyan G, Melendez E, Higuchi Y, et al.
PLoS One
. 2017 May;
12(5):e0177245.
PMID: 28486541
There is currently no FDA approved therapeutic agent for ARS mitigation post radiation exposure. Here we report that the small molecule YH250, which specifically antagonizes p300/catenin interaction, stimulates hematopoiesis in...